Alfonso Tafur: Different Cancer Sites Drive Different Thrombotic Phenotypes
Alfonso Tafur, Vascular Medicine Fellowship Program Director at University of Chicago, Director of Vascular Medicine Department at NorthShore University, shared on LinkedIn:
”For years, many of us have treated cancer-associated thrombosis as if it were a single disease.
The data keep reminding us: it isn’t.
In the RIETE Registry, we looked at 18,000+ cancer patients vs. 88,000 without.
Within 90 days — 2.5× higher recurrent VTE, ~40% higher major bleeding.
But the real signal? Cancer site matters.
Lung and pancreatic drive clot risk. GI and GU drive bleeding risk.
Cancer-associated thrombosis is not one disease.
It is many biologically different thrombotic phenotypes.
Proud to be part of this team working toward precision vascular care.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Mar 9, 2026, 15:36Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access
-
Mar 9, 2026, 15:30Gilles Soulat: Low-Dose Rivaroxaban Plus DAPT for LV Thrombus Prevention After Anterior STEMI
-
Mar 9, 2026, 15:25Jim Hoffman: Exploring Extracorporeal Strategies to Target NETs in Cardiovascular Disease
-
Mar 9, 2026, 15:24Zeeshan Ahmed Khattak: Certification Pathways in Anticoagulation for Pharmacists
-
Mar 9, 2026, 15:20Anthony Yazbeck։ The ‘Golden Blood’ – The World’s Rarest Blood Type
-
Mar 9, 2026, 15:13Ali Al Janaahi: Clinical Insights on Recurrent Stroke in Neuro‑Behçet Disease at DINC 2026
-
Mar 9, 2026, 14:39Tareq Abadl: Quick Clinical Interpretation of Hepatitis B Markers
-
Mar 9, 2026, 14:32Sumedha Dash: What Happens Before a Blood Bag Reaches the Patient?
-
Mar 9, 2026, 14:26Augustina Isioma Ikusemoro: Women Powering the Future of Blood Transfusion